Connecticut’s bioscience industry is an innovative and growing component of the overall U.S. economy. With a track record of generating high-quality jobs and steady growth, the bioscience industry has been a consistent engine for our economy and a key strength during past economic recessions. American innovation in bioscience helps support state and local communities in a variety of ways ranging from job creation, construction, tax revenues, and other economic impact values.

Driven by small-company innovators, the bioscience industry has also mobilized in an unprecedented manner to address the global COVID-19 pandemic, while continuing to develop other life-saving and life-enhancing products and services for the U.S. and the world. America’s bioscience industry as an innovator and economic driver has never been more important, both for our health and our economic stability.

Total Number of Facilities in Connecticut 22
Jobs Directly Supported by the Industry in Connecticut 24251
Annual Average Wage
$136103
Total Clinical Trials
581
Dollar Amount Invested in Clinical Trials
$145.2 Million
Clinical Trial Participants
9582
Total Clinical Trial Economic Impact
$374 Million

View Facilities By District

District Total Facilities in District View Facilities in District
CT01 1

VeraDermics Inc.

CT02 2

American Laboratory Trading (ALT)

BioCT

CT03 17

Artificial Cell Technologies, Inc

Azitra, Inc.

Cybrexa Therapeutics

EpiTET Therapeutics

EvolveImmune Therapeutics, Inc.

Intensity Therapeutics, Inc.

InveniAI LLC

Moexa Pharmaceuticals

NanoViricides, Inc

NextWaveBio

OrphAI Therapeutics

Osmol Therapeutics, Inc.

Rallybio

ReNetX Bio

Trevi Therapeutics, Inc.

Virscio, Inc.

Weave Bio

CT04 2

Boehringer Ingelheim

Braidwell LP